Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.

Ironwood sees Linzess rebounding in 2026 despite soft Q4 results, helped by strong prescription demand and improved net pricing.

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March 11th at 4:00 p.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals is downgraded from a 'Buy' to a 'Sell' due to pipeline setbacks and declining LINZESS sales. IRWD declined to exercise its option on CNP-104 for PBC after disappointing data, removing a key pipeline catalyst. LINZESS U.S. sales dropped 6% to $864.5M in 2025, casting doubt on management's bullish 2026 sales guidance of $1.125–$1.175B.

Ironwood swings to Q4 loss as revenues plunge 47% year over year, missing estimates and sending shares down.

Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2025 Earnings Call Transcript